Invention Grant
- Patent Title: Therapeutic agent for malignant tumors expressing MHC class II
- Patent Title (中): 表达MHC II类恶性肿瘤的治疗剂
-
Application No.: US13877844Application Date: 2011-10-04
-
Publication No.: US09303083B2Publication Date: 2016-04-05
- Inventor: Shuji Matsuoka , Yasuyuki Ishii
- Applicant: Shuji Matsuoka , Yasuyuki Ishii
- Applicant Address: JP Wako-shi JP Tokyo
- Assignee: RIKEN,JUNTENDO EDUCATIONAL FOUNDATION
- Current Assignee: RIKEN,JUNTENDO EDUCATIONAL FOUNDATION
- Current Assignee Address: JP Wako-shi JP Tokyo
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: JP2010-224632 20101004
- International Application: PCT/JP2011/072897 WO 20111004
- International Announcement: WO2012/046745 WO 20120412
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/18 ; C07K16/30

Abstract:
Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56).
Public/Granted literature
- US20130236470A1 THERAPEUTIC AGENT FOR MALIGNANT TUMORS EXPRESSING MHC CLASS II Public/Granted day:2013-09-12
Information query